Linezolid vs no linezolid
Serious adverse events · drug‐resistant pulmonary tuberculosis
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Findings
What do systematic reviews say?
4 questions · 4 findings · 3 reviews · Infectious Diseases
No studies found 1 · 25%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 3 · 75%High 0 · 0%
Gatifloxacin‐containing 4‐month ATT regimens vs standard 6‐month ATT regimen
Serious adverse events · adults with drug‐sensitive pulmonary tuberculosis
Gatifloxacin‐containing 4‐month ATT regimens showed no clear difference in serious adverse events compared with standard 6‐month ATT regimens (moderate certainty).
1 finding from 1 review
- Shortened treatment regimens versus the standard regimen for drug‐sensitive pulmonary tuberculosis 2019 · Cochrane Headline outcomes onlyRR 1.02 [0.58, 1.77]2 studies · 1993 participantsModerate
Moxifloxacin‐containing 4‐month ATT regimens vs standard 6‐month ATT regimen
Serious adverse events · adults with drug‐sensitive pulmonary tuberculosis
Moxifloxacin‐containing 4‐month ATT regimens showed no clear difference in serious adverse events compared with standard 6‐month ATT regimen (moderate certainty).
1 finding from 1 review
- Shortened treatment regimens versus the standard regimen for drug‐sensitive pulmonary tuberculosis 2019 · Cochrane Headline outcomes onlyRR 0.97 [0.74, 1.27]4 studies · 3548 participantsModerate
Intervention not reported
Serious adverse events · treating pulmonary TB
The intervention showed no clear difference in serious adverse events (moderate certainty).
1 finding from 1 review
- Fixed‐dose combinations of drugs versus single‐drug formulations for treating pulmonary tuberculosis 2016 · Cochrane Headline outcomes onlyRR 1.45 [0.9, 2.33]6 studies · 3388 participantsModerate